organizational performance. 8 Measuring both hospital protocol and patient treatment adherence allows targeted improvement, primarily through education and support. Overall performance of program participants is also subject to investigator-based analysis that facilitates improvements. 8, 9 The elements of GWTG-AFIB include site-specific institutional stakeholders, hospital recruitment, collaborative workshops and webinars for hospital teams, hospital tool kits, local clinical opinion leaders, and hospital recognition. 7 Data collection and decision support are performed concurrently using an internet-based Patient Management Tool (Outcome, a Quintiles Company, Cambridge, MA). The collaborative learning model 7 includes interactive learning sessions and other communication between multidisciplinary teams from hospitals to facilitate information transfer to produce system change. System change is generally achieved through the plan-dostudy-act process.
Site Selection
All hospitals will be recruited to participate in GWTG-AFIB by local AHA staff and volunteers, working with key stakeholders in their regions. All hospitals volunteer based on their level of interest in quality improvement in AF care and capacity to fulfill the requirements of the program. Workshops include didactic presentation of clinical trial evidence and the AHA/American College of Cardiology (ACC)/ Heart Rhythm Society guidelines for the treatment of AF, followed by examples of successful hospital implementation. These workshops are given by AHA staff and volunteers with expertise in clinical science and quality improvement and are also used for site recruitment.
Patient Population
Patients aged ≥18 years will be included if they are admitted to the hospital with a principal diagnosis of AF or atrial flutter (in this article, atrial flutter and AF will be considered together as AF). Hospitals are encouraged to enter patients with a secondary diagnosis of AF as well. In addition, hospitals may enter patients seen in observation and not admitted as inpatients. Patients are excluded if they are evaluated, treated, and discharged from the emergency department with no inpatient admission or observation status.
Case ascertainment of admissions for AF will be conducted by concurrent clinical identification (within the current hospitalization) or by retrospective identification using International Classification of Diseases, Ninth Revision (ICD-9) (2) discharge codes 427.31 or 427.32, followed by medical chart review to confirm case eligibility. The coding instructions indicate that a physician must confirm the diagnosis of AF. The AF must be sustained (>30 seconds) and must not have been precipitated by a transient reversible event (such as sepsis or pneumonia where the AF resolves with treatment) if the patient is discharged in normal sinus rhythm without specific AF therapy. The coding instructions are explicit on which therapies are required for inclusion in this scenario. Patients with a documented history of AF are eligible for inclusion. Data from the first 30 patients entered in the Patient Management Tool at each hospital before the start of the intervention will be used as baseline data; the duration of baseline data collection may vary as a function of the hospitals' admission volume.
Hospitals will be characterized based on self-reported status as teaching versus nonteaching (≥1 residency training program) and hospital size (based on number of beds) status. Hospitals will also be characterized based on the presence or absence of a board-certified electrophysiologist on the staff and the presence or absence of an AF ablation program. Data will be collected by participating hospitals without financial compensation.
Oversight and Funding Sources
Oversight of the program is performed by the GWTG Executive and Steering Committees and the AHA Executive Database Steering Committee. Boehringer Ingelheim Pharmaceuticals, Inc, and Daiichi Sanyko, Inc, are national sponsors of the American Heart Association/ American Stroke Association's GWTG-AFIB program but provide no oversight on the goals, execution, or publications of the program.
Data Collection and Components
The data collection tool supports concurrent data collection as well as retrospective data entry; concurrent collection is encouraged as a process improvement goal in each hospital. The case report form is available in Appendix I in the online-only Data Supplement. The coding instructions for the elements of the case report form are in Appendix II in the online-only Data Supplement. The GWTG-AFIB data collection tool includes predefined logic features and user alerts to identify potentially invalid format or values entry. For each hospitalization, the data elements collected and entered into the Patient Management Tool (Table 1 ) provide the basis for describing the demographics as well as understanding the clinical course and therapy of AF for the individual patient and across the population (Figure) . These data elements are common to other ACC/AHA clinical data standard efforts as well as align with other GWTG programs. [10] [11] [12] Additional elements were added to assess the specific needs and therapies warranted for patients with AF based on the ACCF/AHA guidelines and reflect the core achievement, quality, reporting, and descriptive measures established by the GWTG working group. 13 Achievement measures reflect current AHA/ACCF/American Medical Association performance measures for AF, 14 coronary artery disease, 15 and heart failure. 16 Quality measures reflect current ACCF/AHA guidelines, which are not included as performance measures in AF 13 and heart failure. 17 Elements such as demographic data and medical history are captured as they are used for assessing thromboembolic risk and denoting contraindications to various therapies. Information on medications, including specific antiarrhythmic, antiplatelet, and anticoagulant agents, prescribed before and during admission and at discharge (including discharge doses) are also collected so as to define medication utilization within health systems, as well as to determine adherence to evidencebased anticoagulation guidelines. As the current ACCF/AHA guidelines support the use of the CHA 2 DS 2 -VASc 13 score in the evaluation of thromboembolic risk and the indication for anticoagulation therapy, assessment of each of the CHA 2 DS 2 -VASc score components as well as documentation of the score in the medical record is recorded. 13 The CHA 2 DS 2 -VASc score gives a point for each of the following: congestive heart failure, hypertension, age >65 years, diabetes mellitus, female sex, and vascular disease (prior myocardial infarction, peripheral vascular disease, or aortic plaque) and 2 points for each of the following: prior stroke or transient ischemic attack and age >75 years. In the guideline, 13 anticoagulation is recommended for patients with AF and a score of ≥2. The HAS BLED (bleeding risk factors of hypertension, renal disease, liver disease, stroke, labile INR age >/= 65, medication usage predisposing to bleeding, and alcohol usage history) risk calculator is also available on the site. 18 This score is used to calculate the risk of bleeding and includes the following risk factors: hypertension, renal disease, hepatic disease, prior stroke, prior major bleeding or risk of bleeding, labile international normalized ratio, age >65 years, medication use, which predisposes patients to bleeding and heavy alcohol use. The AF guideline 13 does not recommend withholding anticoagulation from patients based on this risk score, however, and thus the calculator is provided for informational purposes only. As monitoring and optimization of drug therapy are critical to improving patient safety and outcomes, documentation of a QT interval after initiation of treatment with dofetilide or sotalol, as well as with any increase in dose is evaluated. In addition, documentation of discharge heart rate is obtained, with a target of ≤110 bpm. Finally, the provision of discharge planning (eg, anticoagulation follow-up) and comprehensive patient education on complications and management of AF is essential in making the transition from hospital to home; therefore, documentation of these efforts are evaluated.
Required fields are structured so that valid data must be entered before the form can be saved as a complete record and the data entered into the database. Range checks are used for inconsistent or out-ofrange data and prompt the user to correct or review data entries that are outside a predefined range. All hospital personnel using the tool receive individual passwords to create an audit trail for data entered or changed. Training in the use of the tool will be provided online and via telephone for all users. This web-based system uses coding, deidentification, and secure transmission techniques that maintain patient confidentiality, in compliance with current federal privacy standards. Data collected by hospitals will not be independently audited by external medical chart review. The working group updates the protocols and data elements every 6 months.
Rapid-Cycle Improvement
One of the primary goals of GWTG-AFIB and other similar programs is to provide an evidence-based set of external metrics that institutions can adapt to facilitate rapid-cycle quality improvement. Passive diffusion of guidelines is rarely sufficient to enact large or lasting changes in clinical practice; additional interventions at the institutional or health system level are often necessary. 19 Effective quality improvement interventions depend on multiple factors, and the most effective interventions usually require a multifaceted approach. 20 A combination of education and outreach, integrated clinical decision support, ongoing audit and feedback, and organizational change geared toward improving specific processes or outcomes are all frequently required for sustained change 21 and allow for rapid-cycle assessment and intervention. 22 GWTG-AFIB encourages and facilitates systematic data acquisition that can be leveraged for quality improvement purposes.
Hospital Recognition
The GWTG-AFIB module will use a Performance Achievement Award recognition program similar to GWTG modules for acute myocardial infarction, heart failure, stroke, and resuscitation. 23, 24 The GWTG-AFIB Performance Achievement Award recognition program was created and will be used to publicly recognize participating hospitals meeting each of the individual GWTG-AFIB achievement measures ( Table 2) in 85% of eligible hospitalizations. There are 3 levels of recognition based on the duration in which measure conformity at the required level has been demonstrated: bronze (1 calendar quarter); silver (1 year); and gold (≥2 years). Silver and gold award-winning GWTG-AFIB 
Primary and Secondary Analyses
GWTG-AFIB was designed as a quality improvement program. Like other GWTG modules, however, it is expected that it will become a robust tool for observational studies. The primary analyses in the GWTG-AFIB program will assess adherence to the ACC/ AHA guideline recommendations and the ACC/AHA AF performance measures, [13] [14] [15] [16] including those for stroke prevention, rate control, and maintenance of sinus rhythm. Measures were divided into achievement measures and quality measures. Percent adherence to each guideline will be reported back to hospitals. The numerator will be defined as those who met the measure minus exclusions and the denominator as those who qualify for the measure criteria minus exclusions (see Appendix III: Measure Definitions in the online-only Data Supplement). Adherence compared with national and regional averages will be reported to hospitals for benchmarking comparisons. Secondary analyses will address multiple aspects of AF care including but not limited to adherence to AF guidelines, sex, race, ethnic, and geographical differences in quality of care, inhospital outcomes including stroke and death, outcomes linked to Medicare patients including mortality and readmission, temporal trends in quality of care, and outcome, and characteristics associated with the use of newer anticoagulant agents in patients with AF. A list of the initially planned analyses targeted at the current gaps in knowledge is listed in Appendix IV in the online-only Data Supplement.
The GWTG-AFIB program will address both contemporary research priorities 25 and those that arise in the lifetime of the program.
The GWTG-AFIB database will likely become a robust tool for answering key questions on the quality of care in patients with AF. Similar to the other Get With The Guidelines registry modules, analysis proposals are submitted to the GWTG Science Subcommittee and reviewed for feasibility, validity, and novelty. 26 The database resides at the biostatistical core center and results of approved analyses are released to investigators.
Statistical Analyses
Continuous variables will be reported via medians with 25th and 75th percentiles, and categorical variables will be shown as counts with percentages. Univariate and multivariable approaches will be used to identify factors associated with measures of interest, including the use of guideline-indicated therapies. Associations between patient characteristics and outcomes of interest via logistic regression will be reported with odds ratios and 95% confidence intervals. Associations will be considered statistically significant when 2-sided α is <0.05. To limit the influence of confounding, multivariable adjustment will be used, including inverse propensity weighting, instrumental variable analysis, or other techniques. Appropriate statistical corrections for repeated measures will be performed. Given the focus on the prevention of stroke and improved survival, standard adjustment models for stroke and all-cause death will be derived and validated for use throughout the program. Missing data will be addressed on an analysis-specific basis. Generalized estimating equations and hierarchical models will be used to adjust for clustering within hospitals when site-specific variance is a concern.
Discussion Although there has been significant growth in the number of AF registries around the world, 1, [27] [28] [29] there are a relatively limited number of large, multicenter, prospective registries enrolling patients in the United States. The Atrial Fibrillation: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry examined practice patterns and guideline adherence among cardiologists treating AF in >1400 outpatients and included 1-year follow-up data. The AFFECTS investigators found that anticoagulation use was often not in line with practice guidelines. 30 More recently, the Outcomes Registry for Better Informed Treatment of AF I & II has begun with a goal enrollment of >25 000 patients with both incident and prevalent AF across a heterogeneous mix of community practices (internal medicine, cardiology, electrophysiology). 31 Figure. Patient Management Tool. This figure shows one of the data entry screens from the Patient Management Tool. It documents that patients have been given education and counseling on tobacco cessation, atrial fibrillation, and anticoagulation. It also documents the treatment strategy for atrial fibrillation and the follow-up strategy for anticoagulation. INR indicates international normalized ratio; and PT, prothrombin time.
These registries will follow patients for a minimum of 2 years. A similar international registry, Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation is also enrolling patients in North America with newly diagnosed AF. Table 3 summarizes the current AF registries.
The GWTG-AFIB registry will complement these and other existing observational studies in several ways. As with other GWTG programs, GWTG-AFIB will be enrolling from a large number of US hospitals and will provide important national data from an inpatient perspective. The core objective of GWTG-AFIB is to provide quality improvement through iterative assessment of guideline-based care. In this way, GWTG-AFIB is unique and will seek to change behavior and improve adherence at the hospital level.
During the past 2 decades, risk factors for stroke in AF have been aggregated into scoring systems to classify patients. The European Society of Cardiology 32 and, most recently, the AHA/ACC/Heart Rhythm Society 13 guidelines have moved to recommending lower treatment thresholds for anticoagulation by changing from the CHADS 2 33 score and adopting the CHA 2 DS 2 -VASc 34 score. This adoption of lower treatment thresholds is, in large part, because of gains in safety and reduced risk of intracranial hemorrhage with new oral anticoagulants, contemporary international normalized ratio management with warfarin, and evidence against the use of aspirin as an effective antithrombotic agent. 35 Therefore, contemporary risk stratification is geared toward sensitivity and negative predictive value; the goal is to identify patients with low stroke risk who do not require treatment, rather than only identifying patients at the highest risk of stroke who require treatment.
Despite guidelines from multiple specialty societies, there remain significant gaps in care of AF. Among inpatients with AF, women, the elderly, 36 and blacks 37 are less likely be discharged on anticoagulation. Potential reasons for these gaps are multifactorial and may include variation in patient education, overtreatment, undertreatment, or differences in familiarity and experience with clinical guidelines. 38 The choice between rate and rhythm control is guided by the presence and severity of symptoms in AF, patient preference, and expected safety of antiarrhythmic drug therapy or catheter ablation. 39 In particular, appropriate selection of antiarrhythmic agents in patients with structural heart disease is critical to minimize adverse events associated with antiarrhythmic drugs.
The ability of programs to improve adherence to guidelines in patients with AF has been variable. Johnston et al 40 randomized 12 hospitals to using preprinted orders, education, and a physician champion. There was no difference between intervention and control hospitals in adherence to anticoagulation guidelines. In the Coverdell quality improvement stroke program, 195 hospitals and 4206 patients with stroke and AF were studied. More than 82% of eligible patients with AF received anticoagulation at discharge. 41 This program used protocols, workshops, and order sets. Piccini et al 42 did not demonstrate improved adherence to anticoagulation guidelines in patients with AF and heart failure in the GWTG Heart Failure program over time. Supporting the performance measure with prompts and making them the focus of the quality improvement program may increase adherence. Lewis et al 43 found that adherence to anticoagulation guidelines did not increase in patients with a history of AF, where anticoagulation was not prompted, but did increase in patients when an ECG demonstrated AF during the hospitalization, where treatment was prompted. Under such circumstances, adherence to anticoagulation in patients with stroke and AF increased to >95%. 44
Limitations
GWTG-AFIB will have several limitations. The GWTG program is voluntary and the hospitals that participate are more likely to be larger teaching hospitals with a strong interest in AF and quality improvement. However, the patient populations in other GWTG registries have been demonstrated to be nationally representative, and there is growing evidence that the selection of participating hospitals in clinical registries does not necessarily result in substantial bias. 45, 46 Participating hospitals are instructed to include all consecutive AF admissions. However, because these processes are not audited, the potential exists for selection bias. Patient data are collected by medical chart review, which is dependent on the accuracy and completeness of documentation. Identifying patients with AF uniformly and accurately can be challenging. It is imperative that registries and quality improvement programs accurately identify eligible patients and minimize variations in case ascertainment. Although trained GWTG abstractors using specific coding instructions may help to increase the accuracy of identifying the appropriate patient population, potential variation in case ascertainment may influence quality assessments and research findings from GWTG-AFIB. Some patients considered eligible for treatment who were not treated may have had contraindications or other reasons that prevented treatment but were not documented in the medical record. Certain data elements that are potentially important such as AF-specific health status instruments are not being collected. However, an audit of GWTG has shown >90% accuracy of these data. 47 GWTG-AFIB defines quality of care using only predefined performance measures and quality measures that address acute and discharge AF care. Patients discharged from the emergency room will not be initially enrolled. Post discharge quality of care and outcomes will not be directly collected.
Conclusions
Although various treatment regimens are available for patients with AF that are effective in reducing morbidity and likely mortality, adherence to guidelines is low. Quality improvement programs such as GWTG-AFIB may increase adherence to guideline-based therapies and potentially improve outcomes. 
